Net sales were $188.6 million, a 7.7% year-over-year increase, according to a news release. Orthofix’s bone growth therapies segment grew 10% year-over-year, and this has been the fifth consecutive quarter with double-digit growth in that area.
Global orthopedic sales were $27.3 million, an increase of 5.1% year-over-year. Global spine sales grew 8.1% year-over-year with $161.3 million.
Orthofix saw a net loss of $36 million. The company is projecting 2024 sales between $790 million to $795 million.
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
